Effects of intravitreal bevacizumab injection on the clinical manifestations of nonproliferative diabetic retinopathy in patients with macular edema: a systematic review

Touka Banaee; Naser Shoeibi; Hosein Ghavam Saeedi

Volume 3, Issue 2 , April 2016, , Pages 63-68

https://doi.org/10.17463/RCM.2016.02.006

Abstract
  Introduction: Bevacizumab (Avastin) is considered as an effective strategy in the treatment of various ocular diseases. As a vascular endothelial growth factor (VEGF) inhibitor, Avastin is used to control macular edema in patients with nonproliferative diabetic retinopathy (NPDR). Therefore, in this ...  Read More

The effect of intravitreal bevacizumab injection on the corneal endothelial cells

Akbar Derakhshan; Alireza Eslampour; Esmaeil Safinezhad; Samira Hasanzadeh

Volume 3, Issue 2 , April 2016, , Pages 78-83

https://doi.org/10.17463/RCM.2016.02.009

Abstract
  Introduction:Bevacizumab (Avastin), as an effectiveness treatment modality, is currently used in patients with various ocular disease. However the results have been promising, the use of bevacizumab in the treatment of ocular disease is an off-label application. Hence, the aim of this study was to systematically ...  Read More